Engineered RNase P Ribozyme Shows Potential in Reducing Human Coronavirus 229E Infections

Strategic Insights -

Researchers from the University of California, Berkeley, have made a breakthrough in developing a novel antiviral strategy to treat and prevent human coronavirus 229E (HCoV-229E) infections. The study, published in the journal Zoonotic Diseases, demonstrates the effectiveness of an engineered RNase P ribozyme in reducing viral RNA levels, N protein expression, and infectious particle production in human cells.

Key Takeaways:

  • The human coronavirus 229E (HCoV-229E) is a member of the human coronavirus family that includes SARS-CoV-2, the causative agent of COVID-19.
  • Ribozymes derived from ribonuclease P (RNase P) catalytic RNA represent a novel class of promising gene-targeting agents.
  • An engineered RNase P ribozyme was designed to target an overlapping region of viral genomic RNA and the mRNA encoding the nucleocapsid (N) protein.
  • The engineered ribozyme was found to effectively hydrolyze the viral RNA target in vitro, reducing viral RNA levels by 85% and N protein expression by 750-fold.
  • The study provides the first direct evidence of the therapeutic potential of RNase P ribozymes against human coronaviruses such as HCoV-229E.
  • The findings have significant implications for the development of antiviral strategies to combat COVID-19 and other coronaviruses.

Statistics:

  • 85% reduction in viral RNA levels in HCoV-229E-infected cells expressing the engineered ribozyme.
  • 750-fold reduction in infectious particle production in HCoV-229E-infected cells expressing the engineered ribozyme.
  • 15% reduction in N protein expression in HCoV-229E-infected cells expressing the engineered ribozyme.

Sources:

  • Zoonotic Diseases, 2025,5(2):12. doi: 10.3390/zoonoticdis5020012
  • University of California, Berkeley. School of Public Health. Department of Virology and Molecular Biology.
  • RNase P ribozymes. Zoonotic Diseases, 2025,5(2):12. doi: 10.3390/zoonoticdis5020012
  • Coronavirus research. University of California, Berkeley. School of Public Health.